Product image of Levosimendan Kalceks (Levosimendan) supplied by GNH India

Levosimendan Kalceks

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Kalceks (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer and inodilator presented as an intravenous solution for intravenous administration. It enhances cardiac contractility and promotes vasodilation, making it suitable for the treatment of acute decompensated heart failure in hospitalized patients.

GNH India supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and specialized cardiac units and intensive care departments worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border procurement.

Manufacturer / TM Owner

Kalceks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.
  • Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
  • Severe left ventricular systolic dysfunction: enhances myocardial contractility to support systemic perfusion.
  • Cardiogenic shock (when conventional therapy is insufficient): provides inotropic support and vasodilation.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load, which together improve overall cardiac performance.

Side Effects

Levosimendan may be associated with several adverse reactions.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea: occasional gastrointestinal upset.
  • Dizziness: related to blood pressure changes.
  • Flushing: warm sensation and skin reddening.
  • Arrhythmia: occasional premature beats.

Serious or Rare Side Effects

  • Severe hypotension: may require intervention.
  • Ventricular arrhythmias: potentially life‑threatening.
  • Myocardial ischemia: chest pain or ECG changes.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Liver enzyme elevation: increased transaminases.
  • Sudden cardiac death: extremely rare but reported.

Precautions & Warnings

  • Levosimendan requires careful clinical monitoring before and during infusion.
  • Monitor blood pressure: watch for significant hypotension.
  • Assess cardiac rhythm: observe for new or worsening arrhythmias.
  • Use cautiously in renal impairment: adjust monitoring and consider dose modification.
  • Avoid in severe hypotension: contraindicated in patients with markedly low blood pressure.
  • Pregnancy: safety unknown; weigh potential benefits against risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid)

  • Concurrent use with other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.
  • Nitrates or phosphodiesterase‑5 inhibitors: may cause profound hypotension.
  • Potassium channel blockers: potential additive vasodilatory effect.

Moderate Interactions (Monitor Closely)

  • Diuretics: may amplify electrolyte shifts and blood pressure changes.
  • ACE inhibitors or ARBs: monitor for enhanced hypotensive response.
  • Beta‑blockers: assess for altered heart rate control.
  • Anticoagulants: observe for bleeding if hypotension occurs.
  • Other vasodilators: titrate to avoid excessive drop in systemic vascular resistance.

Frequently Asked Questions

Levosimendan Kalceks is an intravenous formulation of levosimendan used primarily to treat acute decompensated heart failure in hospitalized patients, helping to improve cardiac output and relieve congestion.

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac after‑load.

The dosing regimen for Levosimendan Kalceks is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Specific dosage instructions are provided in the product’s prescribing information.

The safety of levosimendan in pregnancy and lactation has not been established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and decisions are made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without increasing intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects through potassium‑channel activation, offering a combined inotropic and after‑load‑reducing profile.

Levosimendan Kalceks should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the infusion and discard any solution that appears discolored or particulate.

Levosimendan Kalceks is given as an intravenous infusion. The initial loading dose is usually administered over 10 minutes, followed by a continuous infusion for up to 24 hours, as directed by the treating physician.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of sudden cardiac death. Patients should be closely monitored for hemodynamic changes and cardiac rhythm throughout the infusion.

Levosimendan is contraindicated in patients with severe hypotension, known hypersensitivity to the drug, or those receiving other potent vasodilators that could cause dangerous blood‑pressure drops. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT